Hugo Pinheiro
Name: Hugo Pinheiro
E-mail: hpinheiro@ipatimup.pt
Extension: 
225570700
Academic Degree: Doctor of philosophy


Hugo Pinheiro
Hugo Pinheiro
Member of
External Researcher of Expression Regulation in Cancer


Short CV
Positions held:
January 2012 – Present
Postdoctoral fellow
Ipatimup (Cancer Genetics Group)
CDH1 locus, the next Jekyll and Hyde in cancer? / Professor Carla Oliveira, PhD and Professor David Huntsman, MD

March 2008 – December 2011
PhD Fellow
Ipatimup (Cancer Genetics Group)
E-cadherin: New Regulatory Mechanisms in Cancer / Professor Carla Oliveira, PhD, Professor Elia Stupka and Professor David Huntsman, MD

December 2005 – February 2008
Research Fellow
Ipatimup (Cancer Genetics Group)
Identification of molecular mechanisms underlying gastric cancer in families positive and negative for E-cadherin germline mutations / Professor Carla Oliveira, PhD

June 2005 – November 2005
Research Fellow
IBMC (Basic and Clinical Neurobiology Group)
Excitability of spinal and peripheral sensory neurons and its modulation by local anesthetics / Professor Boris Safronov, PhD

August 2004 – April 2005
Research technician
IBMC (Molecular Neurobiology Group)
Several research projects / Professor Maria João Saraiva, PhD

October 2003 – July 2004
Undergraduate research student
IBMC (Molecular Neurobiology Group)
Role of Transthyretin (TTR) in the Physiology of the Peripheral Nerve / Professor Mónica Sousa, PhD


Academic background:
February 2008 – December 2011
PhD in Biomedicine – Approved by unanimity with distinction
E-cadherin: New Regulatory Mechanisms in Cancer
Ipatimup (Cancer Genetics Group) / Porto University - Faculty of Medicine (FMUP)

December 2005 – December 2007
MSc in Molecular Genetics
E-cadherin silencing: more than inactivating mutations” – Very Good
Ipatimup / Minho University - School of Sciences

October 2000 – July 2004
Degree in Biology – Scientific branch – 15
Porto University - Faculty of Sciences


Highlights
CDH1 encodes for E-cadherin, the central piece for the maintenance of epithelial structure. Described as Tumor-Supressor Gene (TSG) it is impaired in the majority of epithelial cancers and is reported to be a single-transcript gene. This view has been recently challenged with success by our group that has found four novel CDH1 transcripts. One of them, when overexpressed, disrupted E-cadherin function of preventing cell invasion and promoted angiogenesis. We are commited to disclose the mechanisms underlying these effects pinpointing genes/pathways involved. Furthermore, we intend to explore the role of the other transcripts as well as to identify new ones. Our final goal is to disclose new functions enclosed by CDH1 locus and the models where these are fundamental. Doing so we hope to enlarge the knowledge regarding the incomplete landscape of CDH1-regulatory mechanisms in cancer and open novel paths leading to therapeutic strategies concerning tumor initiation and progression.

Supervisor of

PI (running)

PI (closed)
First Author
 
C
IF
Hereditary cancer risk assessment: challenges for the next-gen sequencing era. Frontiers in oncology 5: 62, 2015. [Editorial Material] 
 
Hereditary diffuse gastric cancer - Pathophysiology and clinical management. Best practice & research. Clinical gastroenterology 28: 1055-1068, 2014. [Article] 
 
3. Pinheiro H, Carvalho J, Oliveira P, Ferreira D, Pinto MT, Osório H, Licastro D, Bordeira-Carriço R, Jordan P, Lazarevic D, Sanges R, Stupka E, Huntsman D, Seruca R, Oliveira C
 doi: 10.1093/hmg/dds248 PMID: 22752307.
 
4. Pinheiro H, Bordeira-Carriço R, Seixas S, Carvalho J, Senz J, Oliveira P, Inácio P, Gusmão L, Rocha J, Huntsman D, Seruca R, Oliveira C
Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Human molecular genetics 19: 943-52, 2010. [Article] 
 doi: 10.1093/hmg/ddp537. PMID: 19965908.
 
Senior Author
 
C
IF
Send Email
From
To
Subject